JOHNSON & JOHNSON is 153.1x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($573.98 B vs $3.75 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KNSA | JNJ |
|---|---|---|
| Market cap | $3.75 B | $573.98 B |
| US-listed rank | #1625 | #20 |
| Revenue (latest FY) | $677.56M | $94.19B |
| Net income (latest FY) | $59.01M | $26.80B |
| Net margin | 8.7% | 28.5% |
| P/E (trailing FY) | 63.6 | 21.4 |
| SEC filings | 733 | 984 |
JOHNSON & JOHNSON is 153.1x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($573.98 B vs $3.75 B).
In their latest fiscal years, Kiniksa Pharmaceuticals, Ltd. reported $677.56M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Kiniksa Pharmaceuticals, Ltd. and JOHNSON & JOHNSON, or browse the full rankings.